Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04221815 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact

Study acronym: IMPROVE
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 12, 2025 (before its estimated September 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Apr 2027 to Sep 2026
    • Study completion date: Aug 2027 to Sep 2027
    • Study sites revised (61)
    v16
  2. Primary completion date: Apr 2024 to Apr 2027v15 Show 4 more changesShow less
    • Study sites: 47 to 61
    • Study completion date: Aug 2025 to Aug 2027
    • Interventions: Eagle Eye Platinum digital IVUS catheter with optional SyncVision (Device), Resolute Onyx Drug Eluting Stent (Device) to Eagle Eye Platinum digital IVUS catheter with optional SyncVision (Device), Onyx Frontier Drug Eluting Stent (Device), Onyx TruCor Drug…
    • Eligibility criteria expanded, about 4 words
  3. Site contacts updated at 1 of 47 sitesv14
  4. Study sites: 46 to 47v13
  5. Study sites: 34 to 46v12
Show 10 earlier versionsHide 10 earlier versions
  1. Study sites: 30 to 34v11
  2. Study sites: 23 to 30v10
  3. Study sites: 19 to 23v9
  4. Study sites: 12 to 19v8
  5. Study sites: 8 to 12v7
  6. Study sites: 7 to 8v6
  7. Study sites: 4 to 7v5
  8. Study sites: 1 to 4v4
  9. Lead sponsor: Megan Rowland to Medstar Health Research Institutev3 Show 4 more changesShow less
    • Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 2020 to Oct 14, 2020
    • Study description expanded, about 92 words
    • Study title shortened, about 1 word
  10. Lead sponsor: Rebecca Torguson to Megan Rowland
    • Start date: Feb 2020 to Sep 2020
    • Primary completion date: Sep 2024 to Apr 2024
    • Study completion date: Dec 2024 to Aug 2025
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) has been shown in clinical trials, registries, and meta-analyses to reduce recurrent events after PCI. This is accomplished by improving the angiographic result with lesion and vessel assessment to guide stent selection and implantation and intravascular imaging following stent implantation to ensure an adequate treatment endpoint has been achieved. Despite extensive literature supporting the use of IVUS in PCI, utilization remains low in the United States. An increasing number of high-risk or complex lesions are being treated with PCI and we hypothesize that the impact of IVUS in these complex lesions will be of increased importance in reducing clinical adverse events while remaining cost effective.
Trial Details
NCT Number NCT04221815
Lead Sponsor Medstar Health Research Institute
Conditions
(from sponsor)		 Atherosclerosis
Related terms Atherosclerosis
Enrollment 3,100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov